Effect of 3-hydroxy-3-methylglutarylcoenzyme A Reductase Inhibitors (Statins) on Tissue Paraoxonase 1 and Plasma Platelet Activating Factor Acetylhydrolase Activities

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 1, 2004, Pages 121-127

  Bełtowski, Jerzy ^a   Wójcicka, Grazyna ^a   Jamroz, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Atherosclerosis; Fluvastatin; Oxidative stress; Paraoxonase; Platelet activating factor acetylhydrolase; Pravastatin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARAOXON; PHENYLACETIC ACID DERIVATIVE; PRAVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HEART; KIDNEY CORTEX; KIDNEY MEDULLA; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; FATTY ACIDS, MONOUNSATURATED; HEART; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER; MALE; PRAVASTATIN; RATS; RATS, WISTAR;

EID: 0347594016     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200401000-00018     Document Type: Article

References (49)

1. Scandinavian Simvastatin Survival Study (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
3. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
4. McFarlane SI, Muniyappa R, Francisco R, et al. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87:1451-1458.
5. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J. 2003;24:225-248.
6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
7. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-480.
8. Jakubowski H. Calcium-dependent human serum homocysteine thiolactono hydrolase. J Biol Chem. 2000;275:3957-3962.
9. Draganov DI, Stetson PL, Watson CE, et al. Rabbit serum paraoxonase-3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2001;275:33435-33442.
10. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21:542-547.
11. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001;276:44444-44449.
12. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.
13. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479-487.
14. Karabina SA, Elisaf M, Bairaktari E, et al. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subtractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997;27:595-602.
15. Paekard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148-1155.
16. Bełtowski J, Wójcicka G, Mydlarczyk M, et al. Cerivastatin modulates plasma paraoxonase/arylesterasc activity and oxidant-antioxidant balance in the rat. Pol J Pharmacol. 2002;54:143-150.
17. Bełtowski J, Wójcicka G, Jamroz A. Differential effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. Pol J Pharmacol. 2002;54:661-671.
18. Hernandez RL, AF, Lopez-Caballero JJ, et al. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact. 2001;137:123-137.
19. Schiavon R, De Fanti E, Giavarina D, et al. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta. 1996;247:71-80.
20. Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330-335.
21. Pond AL, Chambers HW, Coyne CP, et al. Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon. J Pharmacol Exp Ther. 1998;286:1404-1411.
22. Lowry OH, Rosenbrough NI, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
23. Kosaka T, Yamaguchi M, Soda Y, et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta. 2000;296:151-161.
24. Kosaka T, Yamaguchi M, Miyanaga K, et al. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin Chim Acta. 2001;312:179-183.
25. Gouedard C, Koum-Besson N, Barouki R, et al. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol. 2003;63:945-956.
26. Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2000;20:2113-2119.
27. Leview I, James R. Simvastatin increases plasma level of the antioxidant enzyme paraoxonase by PON1 gene activation. Atherosclerosis. 2001;151(suppl):41.
28. Balogh Z, Fulop P, Seres I, et al. Effects of simvastatin on serum paraoxonase activity. Clin Drug Invest. 2001;21:505-510.
29. Fuhrman B, Koren L, Volkova N, et al. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis. 2002;164:179-185.
30. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002;22:306-311.
31. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193-199.
32. Krause BR, Princen HM. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis. 1998;140:15-24.
33. Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res. 2001;89:415-421.
34. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis. 1995;117:237-244.
35. Sorenson RC, Bisgaier CL, Aviram M, et al. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999;19:2214-2225.
36. Kudchodkar BJ, Lacko AG, Dory L, et al. Dietary fat modulates serum paraoxonase 1 activity in rats. J Nutr. 2000;130:2427-2433.
37. Corsini A, Pazzucconi F, Pfister P, et al. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet. 1996;348:1584.
38. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
39. Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol. 2000;35:256-262.
40. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
41. Waldman A, Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs. 2003;63:139-152.
42. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 2001;111:390-400.
43. Goldberg AC. Clinical implications of statin event trials. Curr Atheroscler Rep. 2002;4:337-342.
44. Guerra R, Zhao B, Mooser V, et al. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997;38:2281-2288.
45. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002;22:306-311.
46. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res. 2002;43:256-263.
47. Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. 2000;14:2032-2039.
48. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
49. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.